Key result
Pre-procedural DAPT linked to ~4.3-fold higher access-site vascular complications after TAVI with MANTA VCD.
Why the study?
The plug-based MANTA VCD is associated with higher rates of vascular complications after transfemoral TAVI, but the predictors and mid-term outcomes of these complications were not well analyzed.
What are the predictors and mid-term outcomes of access-site related vascular complications in patients undergoing transfemoral TAVI with the MANTA vascular closure device?
RCT (n=237)
Randomized to vascular closure with the MANTA VCD
No
What are the predictors and mid-term outcomes of access-site related vascular complications in patients undergoing transfemoral TAVI with the MANTA vascular closure device?
Pre-procedural dual antiplatelet therapy independently increases the risk of vascular complications by over four-fold in TAVI patients treated with the MANTA closure device, though affected patients experience no late-onset access-site events at mid-term follow-up.
Answers are grounded in this paper and cite their sources.
Pre-procedural DAPT may increase MANTA-related vascular complications after TAVI; leaves open optimal regimen in prospective trials.
Background The plug‐based MANTA (Teleflex, Pennsylvania, USA) vascular closure device (VCD) is an alternative to suture‐based VCDs for large‐bore arterial closure after transcatheter aortic valve implantation (TAVI), but has been associated with higher rates of vascular complications. Predictors and outcomes of these complications are not well‐analyzed, especially regarding the self‐resorbing characteristics of the MANTA VCD. Objectives To identify predictors of access‐site related vascular complications following transfemoral TAVI with the MANTA VCD, and to assess mid‐term outcomes and late‐onset events (after 30 days) in affected patients. Methods This prospective substudy of the CHOICE‐CLOSURE trial included all patients randomized to vascular closure with the MANTA VCD at the Leipzig Heart Center. Patients with vascular complications, defined according to the Valve Academic Research Consortium (VARC)‐2 criteria, underwent additional clinical and ultrasound follow‐up, at least 6 months after the index procedure. Predictors of vascular complications were assessed through multivariable analysis. Results Of 237 patients treated with the MANTA VCD, 46 (19.4%) had an access‐site related vascular complication. Pre‐procedural dual antiplatelet therapy (DAPT) was the only independent predictor in multivariable analysis (Odds ratio 4.27, 95% confidence interval 1.58–11.59, p = 0.004). At a mean follow‐up of 13.5 months, no new vascular complications occurred. Patients with an over‐stented MANTA VCD ( n = 5) had no in‐stent stenosis, and stent diameters further expanded by 12.5% to 20.0%. Conclusion Pre‐procedural DAPT independently predicted vascular complications after TAVI in MANTA patients. Patients with vascular complications had no further access‐site late‐onset events, and endovascular stenting of a MANTA VCD appeared safe.
No takes yet. Share an insight, caveat, or question.
Roeßler et al. (2026) conducted an RCT in Aortic stenosis undergoing transfemoral TAVI with MANTA vascular closure device (n=237). Pre-procedural dual antiplatelet therapy (DAPT) in patients treated with MANTA VCD vs. No pre-procedural DAPT was evaluated on Access-site related vascular complications (VARC-2 criteria) (OR 4.27, 95% CI 1.58-11.59, p=0.004). Pre-procedural DAPT independently predicted access-site vascular complications after TAVI with MANTA VCD, with no late events at 13.5 months.
Synapse has enriched 10 related papers. Consider them for comparative context: